Table 4

Baseline predictors of maintaining the T2T states during the study in patients with at least 1 year of follow-up*

	N	Low-CS		SLEDAI-LD		LLDAS		Any T2T
	N	Median (IQR) proportion of follow-up in state†	P value	Median (IQR) proportion of follow-up in state)	P Value	Median (IQR) proportion of follow-up in state	P value	Median (IQR) proportion of follow-up in state	P value
Renal involvement
No	103	0.86 (0.57–1.0)		0.93 (0.73–1.0)		0.41 (0.22–0.67)		1.00 (0.88–1.0)
Yes	41	0.50 (0.18–0.91)		0.55 (0.29–0.83)		0.17 (0–0.5)		0.80 (0.47–1.0)
Race
Non-white	63	0.60 (0.25–0.88)	<0.0001	0.71 (0.33–1.0)	0.0026	0.27 (0.04–0.5)	0.0013	0.9 (0.54–1.0)	0.0007
White	81	0.94 (0.63–1.0)	<0.0001	0.88 (0.76–1.0)	0.0026	0.43 (0.25–0.71)	0.0013	1.00 (0.9–1.0)	0.0007
Registry entry at the time of diagnosis
No	54	0.77 (0.36–1.0)	0.7926	0.78 (0.5–1.0)	0.1027	0.38 (0.09–0.73)	0.9357	1.00 (0.68–1.0)	0.2542
Yes	90	0.75 (0.5–1.0)	0.7926	0.88 (0.62–1.0)	0.1027	0.4 (0.15–0.62)	0.9357	1.00 (0.85–1.0)	0.2542
SDI score of 0 at baseline
No	21	0.57 (0.11–0.73)	0.0033	0.63 (0.27–0.87)	0.0175	0.26 (0–0.4)	0.0271	0.83 (0.5–1.0)	0.0033
Yes	123	0.82 (0.52–1.0)	0.0033	0.87 (0.62–1.0)	0.0175	0.40 (0.15–0.67)	0.0271	1.00 (0.84–1.0)	0.0033
In low-CS at baseline
No	54	0.46 (0.1–0.67)	<0.0001	0.67 (0.3–0.93)	<0.0001	0.22 (0–0.4)	<0.0001	0.79 (0.5–0.97)	<0.0001
Yes	90	1.00 (0.73–1.0)	<0.0001	0.91 (0.75–1.0)	<0.0001	0.50 (0.26–0.71)	<0.0001	1.00 (0.96–1.0)	<0.0001
In SLEDAI-LD at baseline
No	53	0.59 (0.19–0.91)	<0.0001	0.55 (0.29–0.8)	<0.0001	0.17 (0–0.4)	<0.0001	0.78 (0.5–0.96)	<0.0001
Yes	91	0.90 (0.6–1.0)	<0.0001	1.00 (0.83–1.0)	<0.0001	0.47 (0.27–0.71)	<0.0001	1.00 (0.97–1.0)	<0.0001
In LLDAS at baseline
No	103	0.68 (0.35–0.93)	<0.0001	0.80 (0.46–0.93)	<0.0001	0.27 (0.05–0.44)	<0.0001	0.92 (0.68–1.0)	<0.0001
Yes	41	1.00 (0.88–1.0)	<0.0001	1.00 (0.86–1.0)	<0.0001	0.71 (0.48–.85)	<0.0001	1.00 (1.0–1.0)	<0.0001
In any of the T2T states at baseline
No	29	0.30 (0.08–0.63)	<0.0001	0.40 (0.25–0.67)	<0.0001	0.10 (0–0.25)	<0.0001	0.59 (0.4–0.78)	<0.0001
Yes	115	0.92 (0.59–1.0)	<0.0001	0.92 (0.75–1.0)	<0.0001	0.43 (0.26–.69)	<0.0001	1.00 (0.92–1.0)	<0.0001

*P values from univariate analysis and applied Wilcoxon rank-sum test to evaluate statistically significant differences between groups.
†1.0 reflects 100% median of 100% of follow-up time of 1 or more years.
CS, corticosteroid; LLDAS, lupus low disease activity state; low-CS, limited corticosteroid use; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLEDAI-LD, SLEDAI score of <4; T2T, treat-to-target.